spacer
home > ict > summer 2019 > post-marketing pharmacovigilance
PUBLICATIONS
International Clinical Trials

Post-Marketing Pharmacovigilance




European legislation requires that marketing authorisation holders (MAHs) should have an appropriate system for pharmacovigilance (PV) in place. Since the introduction of the updated legislation in July 2012, a set of guidelines for the conduct of PV has been developed by the EMA, known as good pharmacovigilance practice (GVP) modules, to support its implementation (1-4). Each GVP module covers one major PV process. The obligations are the same regardless of the MAH size or if the MAH is an innovative or a generic pharmaceutical company. However, the legislation and regulations do not stipulate how the MAH fulfils these obligations. It is up to the individual MAH to interpret the legislation and regulations and present, at audits and inspections, a system that complies with the requirements.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
About the authors


Emma Boulton is the Head of Pharmacovigilance for UK and Ireland at Napp Pharmaceuticals. She has over 20 years of PV experience in both preand post-marketing. Emma is a serving committee member of PIPA and the Co-Chair of the PIPA training working party. Emma is a qualified nurse and holds a post-graduate diploma in Pharmacovigilance.



Dora Amene is the Pharmacovigilance Manager at TMC Pharma Services. She is a serving committee member of PIPA and Co-Editor for PIPA’s journal, which is published at least three times a year. Dora has a Master’s degree in Pharmacovigilance and seven years of PV experience in post-marketing and, recently, in clinical.


Print this page
Send to a friend
Privacy statement
News and Press Releases

PCI Pharma Services Announces Further Expansion in San Diego to Maintain Industry-Leading Quality, Service and Flexibility

Philadelphia, PA – June 4, 2019 PCI Pharma Services (PCI), a leading biopharmaceutical outsourcing services provider, has announced the growth of its West Coast Clinical operations with expansion into its third facility in San Diego.
More info >>

White Papers

Is Your Biobank Ready for the Challenge of Biomarker-based Research?

BioFortis

Targeted and personalized studies with well-defined patient segmentation biomarkers are becoming the norm in clinical trials. This increased interest in molecular biomarker studies necessitates a rigor and sophistication in sample management within the clinical trial context that is often not supported either by traditional clinical trial management software (CTMS), or biobanking systems.  Download our Next Generation Biobanking whitepaper and learn about how to overcome the key challenges in clinical trial sample management from working in a distributed network of partners and stakeholder to managing consents and generating scientific insights.
More info >>

 
Industry Events

CPhI & P-MEC India

26-28 November 2019, India Expo Centre, Greater Noida, Delhi NCR, India

As the pharma industry looks increasingly towards India forhigh quality, low   cost pharma solutions, CPhI & P-MEC Indiais the ideal event for companies wanting to pick up on the latest trends and innovations the market has to offer. At CPhI & P-MEC India, you will meet the movers and shakers from India’s pharma machinery, technology and ingredients industries, giving you a competitive advantage that will help grow your business.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement